Prospective validation of the PML risk biomarker l-selectin and influence of natalizumab extended intervals
Von Schwab et al, erschienen in „Neurology“ (Vol. 93, Nr. 17, September 2019)
Von Schwab et al, erschienen in „Neurology“ (Vol. 93, Nr. 17, September 2019)